Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Darvadstrocel - TiGenix

Drug Profile

Darvadstrocel - TiGenix

Alternative Names: Alofisel; Cx-601

Latest Information Update: 25 Nov 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Cellerix
  • Developer La Fundacion para la Investigacion Biomedica del Hospital Universitario La Paz; Takeda; TiGenix
  • Class Stem cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Rectal fistula
  • New Molecular Entity No

Highest Development Phases

  • Registered Rectal fistula
  • No development reported Rectovaginal fistula; Ulcerative colitis

Most Recent Events

  • 15 Oct 2019 Millennium Pharmaceuticals initiates a long term follow up phase III trial in Rectal fistula in Czech Republic and Spain (NCT04075825; EudraCT2019-000333-39)
  • 02 Sep 2019 Takeda plans a phase III trial for Crohn's Disease and Rectal fistula (Intraleisonal) in October 2019 (NCT04075825)
  • 18 May 2019 Updated efficacy and adverse events data from the phase III ADMIRE-CD trial for Rectal fistula presented at the Digestive Disease Week 2019 (DDW-2019)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top